Werewolf Therapeutics, Inc. – NASDAQ:HOWL
Founder-led company
Werewolf Therapeutics stock price today
$1.27
-0.28
-18.06%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 5 hours
Werewolf Therapeutics stock price monthly change
-42.38%
month
Werewolf Therapeutics stock price quarterly change
-42.38%
quarter
Werewolf Therapeutics stock price yearly change
-60.15%
year
Werewolf Therapeutics key metrics
Market Cap | 69.07M |
Enterprise value | N/A |
P/E | -1.33 |
EV/Sales | -2.36 |
EV/EBITDA | 0.74 |
Price/Sales | 4.62 |
Price/Book | 0.62 |
PEG ratio | -0.01 |
EPS | -1.08 |
Revenue | 16.22M |
EBITDA | -44.08M |
Income | -41.57M |
Revenue Q/Q | -83.37% |
Revenue Y/Y | -22.25% |
Profit margin | -328.09% |
Oper. margin | -261.43% |
Gross margin | 44.41% |
EBIT margin | -261.43% |
EBITDA margin | -271.77% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeWerewolf Therapeutics stock price history
Werewolf Therapeutics stock forecast
Werewolf Therapeutics financial statements
| Jun 2023 | 8.08M | -5.09M | -63.09% |
|---|---|---|---|
| Sep 2023 | 5.89M | -8.28M | -140.5% |
| Dec 2023 | 1.50M | -12.00M | -799.67% |
| Mar 2024 | 742K | -16.19M | -2182.35% |
| Oct 2025 | 802.89K | -20.39M | -2540.55% |
|---|---|---|---|
| Dec 2025 | 813.51K | -17.53M | -2156.01% |
| Mar 2026 | 824.28K | -16.99M | -2061.48% |
| Jul 2026 | 835.19K | -18.29M | -2190.48% |
Analysts Price target
Financials & Ratios estimates
| 2023-11-14 | -0.27 | -0.23 |
|---|---|---|
| 2024-03-07 | -0.43 | -0.33 |
| 2024-05-03 | -0.35 | -0.39 |
| Jun 2023 | 185235000 | 66.63M | 35.97% |
|---|---|---|---|
| Sep 2023 | 176386000 | 2.40M | 1.36% |
| Dec 2023 | 174833000 | 63.45M | 36.3% |
| Mar 2024 | 177600000 | 60.01M | 33.79% |
| Jun 2023 | -10.92M | -182K | 692K |
|---|---|---|---|
| Sep 2023 | -7.20M | -221K | 41K |
| Dec 2023 | -4.58M | -198K | 9.07M |
| Mar 2024 | -15.29M | -111K | 20.25M |
Werewolf Therapeutics alternative data
| Aug 2023 | 46 |
|---|---|
| Sep 2023 | 48 |
| Oct 2023 | 48 |
| Nov 2023 | 48 |
| Dec 2023 | 46 |
| Jan 2024 | 46 |
| Feb 2024 | 46 |
| Mar 2024 | 47 |
| Apr 2024 | 47 |
| May 2024 | 47 |
| Jun 2024 | 46 |
| Jul 2024 | 46 |
Werewolf Therapeutics other data
36.02%
-34.17%
of HOWL is owned by hedge funds
17
-20
10.39M
-10.49M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2023 | 1853000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | RA CAPITAL MANAGEMENT, L.P. director | Common Stock | 1,853,000 | $2.21 | $4,095,130 | ||
Option | SEIDEL-DUGAN CYNTHIA officer: Chief Sc.. | Stock Option (right to buy) | 15,532 | $4.77 | $74,088 | ||
Option | SEIDEL-DUGAN CYNTHIA officer: Chief Sc.. | Stock Option (right to buy) | 24,199 | $1.56 | $37,750 | ||
Option | SEIDEL-DUGAN CYNTHIA officer: Chief Sc.. | Common Stock | 15,532 | $4.77 | $74,088 | ||
Option | SEIDEL-DUGAN CYNTHIA officer: Chief Sc.. | Common Stock | 24,199 | $1.56 | $37,750 | ||
Option | LEONARD REID officer: Chief Operating Officer | Stock Option (Right to Buy) | 14,102 | $1.56 | $21,999 | ||
Option | LEONARD REID officer: Chief Operating Officer | Common Stock | 14,102 | $1.56 | $21,999 | ||
Sale | LEONARD REID officer: Chief Operating Officer | Common Stock | 135 | $13.97 | $1,886 | ||
Sale | LEONARD REID officer: Chief Operating Officer | Common Stock | 2,865 | $13.39 | $38,357 | ||
Purchase | RA CAPITAL MANAGEMENT, L.P. | Common Stock | 9,285 | $13.37 | $124,140 |
| Patent |
|---|
Application Filling date: 22 Feb 2022 Issue date: 14 Jul 2022 |
Application Filling date: 10 Nov 2021 Issue date: 24 Feb 2022 |
Application Filling date: 14 May 2021 Issue date: 30 Dec 2021 |
Application Filling date: 22 Sep 2020 Issue date: 6 May 2021 |
Application Filling date: 28 Oct 2020 Issue date: 22 Apr 2021 |
Application Filling date: 21 May 2020 Issue date: 10 Sep 2020 |
Application Filling date: 21 May 2020 Issue date: 10 Sep 2020 |
Grant Filling date: 11 Jun 2019 Issue date: 30 Jun 2020 |
Grant Filling date: 11 Jun 2019 Issue date: 30 Jun 2020 |
Application Filling date: 11 Jun 2019 Issue date: 6 Feb 2020 |
Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space
Werewolf Therapeutics: Still In The Race To Develop Next Generation Cytokines
Werewolf Therapeutics: Possibly A Transformative IL-2, But Still Early Days
Werewolf: Q4 2023 Data Readout And Enhancement Of Validated Targets
Medicenna: Presenting Data Next Week Plus A Clinical Update Next Quarter
Werewolf Therapeutics: A Clinical Stage Biotech On The Hunt For Results In 2023
Medicenna: Multiple Catalysts Ahead In 2023
MDA Breakout Stocks Week 37 - September 2022: Short-Term Picks To Give You An Edge
Jazz Pharmaceuticals: Strong Launch Of Xywav In Idiopathic Hypersomnia
-
What's the price of Werewolf Therapeutics stock today?
One share of Werewolf Therapeutics stock can currently be purchased for approximately $1.27.
-
When is Werewolf Therapeutics's next earnings date?
Unfortunately, Werewolf Therapeutics's (HOWL) next earnings date is currently unknown.
-
Does Werewolf Therapeutics pay dividends?
No, Werewolf Therapeutics does not pay dividends.
-
How much money does Werewolf Therapeutics make?
Werewolf Therapeutics has a market capitalization of 69.07M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 21.6% to 19.94M US dollars. Werewolf Therapeutics made a loss 37.37M US dollars in net income (profit) last year or -$0.39 on an earnings per share basis.
-
What is Werewolf Therapeutics's stock symbol?
Werewolf Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "HOWL".
-
What is Werewolf Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Werewolf Therapeutics?
Shares of Werewolf Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Werewolf Therapeutics's key executives?
Werewolf Therapeutics's management team includes the following people:
- Dr. Daniel J. Hicklin Founder, Chief Executive Officer, Pres, Sec. & Director(age: 61, pay: $618,940)
- Dr. Cynthia Seidel-Dugan Ph.D. Chief Scientific Officer(age: 66, pay: $444,400)
- Dr. Randi Isaacs M.D. Chief Medical Officer(age: 69, pay: $333,170)
-
Is Werewolf Therapeutics founder-led company?
Yes, Werewolf Therapeutics is a company led by its founder Dr. Daniel J. Hicklin.
-
How many employees does Werewolf Therapeutics have?
As Jul 2024, Werewolf Therapeutics employs 46 workers, which is 2% less then previous quarter.
-
When Werewolf Therapeutics went public?
Werewolf Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 30 Apr 2021.
-
What is Werewolf Therapeutics's official website?
The official website for Werewolf Therapeutics is werewolftx.com.
-
Where are Werewolf Therapeutics's headquarters?
Werewolf Therapeutics is headquartered at 1030 Massachusetts Avenue, Cambridge, MA.
-
How can i contact Werewolf Therapeutics?
Werewolf Therapeutics's mailing address is 1030 Massachusetts Avenue, Cambridge, MA and company can be reached via phone at +61 79520555.
Werewolf Therapeutics company profile:
Werewolf Therapeutics, Inc.
werewolftx.comExchange:
NASDAQ
Full time employees:
45
Industry:
Biotechnology
Sector:
Healthcare
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
1030 Massachusetts Avenue
Cambridge, MA 02138
Cambridge, MA 02138
CIK: 0001785530
ISIN: US95075A1079
CUSIP: 95075A107
